GlassScriptPhysician profile
Dauris Figueras
NPI 1073683132
$7,338.31
in general payments reported to CMS, 2019-2025
36 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what a typical Obesity Medicine (Preventive Medicine) provider received nationally (typical 2025 total: $203).
See the full distribution for Obesity Medicine (Preventive Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $962 · 2021: $326 · 2022: $1,050 · 2023: $1,252 · 2024: $1,307 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,971 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,970.77 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,269.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $965.87 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $836.52 | 2019-2025 | |
| Amarin Pharma, INC. | $697.29 | 2019-2022 | |
| Lilly USA, LLC | $509.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $383.41 | 2020-2025 | Repatha, Otezla, Repatha |
| Radius Health, INC. | $359.72 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $313.49 | 2019-2025 | Zoryve |
| Exact Sciences Corporation | $256.65 | 2023-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $202.62 | 2022-2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Abbott Laboratories | $200.59 | 2022-2025 | Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.98 | 2019-2025 | Xifaxan |
| Dexcom, INC. | $102.40 | 2023-2025 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $101.65 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.87 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $74.28 | 2025 | |
| Amneal Pharmaceuticals LLC | $69.03 | 2022-2024 | Unithroid |
| Idorsia Pharmaceuticals US INC | $68.41 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $65.38 | 2022-2024 | Onzetra Xsail, Contrave |
| Astellas Pharma US INC | $64.55 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $63.13 | 2024-2025 | Voquezna |
| Abbvie INC. | $61.55 | 2023-2024 | |
| Ibsa Pharma INC. | $55.00 | 2019-2025 | Tirosint, Tirosint, Flector |
| Optinose US, INC. | $51.06 | 2025 | |
| Esperion Therapeutics, INC. | $43.26 | 2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $33.76 | 2019 | |
| Merck Sharp & Dohme LLC | $33.07 | 2019-2020 | |
| Cmp Pharma, INC. | $31.77 | 2022 | |
| Vanda Pharmaceuticals INC. | $30.72 | 2023 | Fanapt, Hetlioz |
| Mission Pharmacal Company | $23.23 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.94 | 2023 | Gvoke Hypopen |
| Merz North America, INC. | $20.83 | 2025 | |
| Acadia Pharmaceuticals INC | $19.68 | 2022 | |
| Genentech USA, INC. | $18.24 | 2019 | |
| Glaxosmithkline, LLC. | $17.66 | 2019 | |
| Sanofi Pasteur INC. | $17.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dauris Figueras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.